Lisata Therapeutics Inc. Market Cap ($11.45 Million)
Market Cap & Net Worth: Lisata Therapeutics Inc. (LSTA)
Lisata Therapeutics Inc. market cap. Lisata Therapeutics Inc. (NASDAQ:LSTA) has a market capitalization of $11.45 Million ($11.45 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26566 globally and #5553 in its home market, demonstrating a 2.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lisata Therapeutics Inc.'s stock price $1.09 by its total outstanding shares 10804066 (10.80 Million). Also see Lisata Therapeutics Inc. cash conversion from operations for how efficiently the company converts equity into cash flow.
Lisata Therapeutics Inc. Market Cap History (2015–2026)
Lisata Therapeutics Inc. market cap history from 2015 to 2026. Data shows change from $1.75 Billion to $11.78 Million (-37.59% CAGR). Check LSTA stock price for real-time trading data and today's change.
Index Memberships
Lisata Therapeutics Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #745 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2428 of 3165 |
Weight: Lisata Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lisata Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lisata Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LSTA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
118.21x
Lisata Therapeutics Inc.'s market cap is 118.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $458.63 Million | $35.28 Million | -$32.66 Million | 13.00x | N/A |
| 2022 | $27.33 Million | $121.37 Million | -$54.23 Million | 0.23x | N/A |
| 2024 | $32.20 Million | $1.00 Million | -$19.98 Million | 32.20x | N/A |
| 2025 | $20.10 Million | $170.00K | -$16.59 Million | 118.21x | N/A |
Competitor Companies of LSTA by Market Capitalization
Companies near Lisata Therapeutics Inc. in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Lisata Therapeutics Inc. for a full breakdown of the balance sheet.
Key companies related to Lisata Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Lisata Therapeutics Inc. (2015–2026)
Market capitalization of Lisata Therapeutics Inc. from 2015 to today. Between 2015 and today, Lisata Therapeutics Inc.'s market cap moved from $1.75 Billion to $ 11.78 Million, with a yearly change of -37.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.78 Million | -41.40% |
| 2025 | $20.10 Million | -37.58% |
| 2024 | $32.20 Million | +9.16% |
| 2023 | $29.50 Million | +7.91% |
| 2022 | $27.33 Million | -79.92% |
| 2021 | $136.13 Million | -41.26% |
| 2020 | $231.75 Million | -43.03% |
| 2019 | $406.77 Million | -29.49% |
| 2018 | $576.94 Million | +1.42% |
| 2017 | $568.83 Million | +24.03% |
| 2016 | $458.63 Million | -73.80% |
| 2015 | $1.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Lisata Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.45 Million USD |
| MoneyControl | $11.45 Million USD |
| MarketWatch | $11.45 Million USD |
| marketcap.company | $11.45 Million USD |
| Reuters | $11.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more